U.S. Pharma Stock News

FirstSun Capital Bancorp (NasdaqGS:FSUN) has been removed from the Russell 2000 Defensive Index. The company has also been dropped from the Russell 2500 Defensive, Russell 2500 Value-Defensive, and Russell 2000 Value-Defensive indices. This index reclassification affects how some passive and rules based funds may hold or view the stock. FirstSun Capital Bancorp, the holding company for FirstBank, operates as a regional banking platform focused on commercial and consumer financial services...

TJX Companies (NYSE:TJX) announced a 13% increase in its quarterly dividend. This is the 29th dividend increase approved by the Board in the past 30 years. The company reaffirmed plans to repurchase up to US$2.75b of shares during Fiscal 2027. TJX Companies, the off price retailer behind T.J. Maxx, Marshalls and HomeGoods, is signaling confidence through higher cash returns to shareholders. A 13% dividend increase and a reinforced buyback plan highlight how management is choosing to deploy...

TD SYNNEX (SNX) opened fiscal 2026 with Q1 revenue of US$17.2b and basic EPS of US$4.09, setting the tone against a trailing twelve month backdrop of US$65.1b in revenue and US$12.06 in EPS. Over the past year, revenue has moved from US$58.5b to US$65.1b on a trailing basis, while EPS over the same window has shifted from US$7.99 to US$12.06. This provides a clear view of how the top and bottom lines have tracked into this latest quarter. For investors, the key question now is how sustainably...

If you are wondering whether Alamo Group's current share price still offers value, it helps to step back and look at what the recent moves might be telling you about expectations built into the stock. The shares recently closed at US$164.97, with returns of 3.7% decline over 7 days, 22.7% decline over 30 days, 3.2% decline year to date, 7.6% decline over 1 year, 4.9% decline over 3 years, and 6.6% gain over 5 years. Taken together, this gives you a mixed picture of how the market has priced...

In the most recent quarter, Fresh Del Monte Produce delivered an exceptional Q4, surpassing analyst estimates on earnings per share and gross margins through firm pricing, sustained demand in core categories, and tight cash flow management. This strong execution across the business highlights how disciplined pricing and cash generation can strengthen the company’s financial profile even in a challenging cost backdrop. Next, we’ll examine how this earnings beat and margin strength might...

In the last week, the United States market has stayed flat but is up 16% over the past year, with earnings forecasted to grow by 15% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for sustained revenue and earnings expansion in alignment with these broader market trends.

Over the last 7 days, the United States market has remained flat, yet it is up 16% over the past year with earnings forecast to grow by 15% annually. In this environment, identifying stocks that are trading at a discount can offer potential opportunities for investors seeking value in a growing market.

In the last week, the United States market has stayed flat, yet it has risen by 16% over the past year with expectations of a 15% annual earnings growth in the coming years. In this context, identifying growth companies with high insider ownership can be advantageous as they often align management interests with shareholder value and may capitalize on favorable market conditions.

The market remained flat over the last week, but it is up 16% over the past year, with earnings expected to grow by 15% annually in the coming years. For those interested in smaller or newer companies, penny stocks—despite their somewhat outdated name—can still offer surprising value and potential for growth. By focusing on stocks with strong financial foundations, investors may find opportunities that combine stability with promising prospects.

Over the last 7 days, the United States market has remained flat, yet it boasts a notable 16% rise over the past year with earnings forecasted to grow by 15% annually. In such a dynamic environment, discovering promising small-cap stocks that have potential for growth can be key to capitalizing on these positive trends.

Over the last 7 days, the United States market has remained flat, though it has experienced a robust 16% increase over the past year, with earnings expected to grow by 15% per annum in the coming years. In this context of steady growth and positive earnings projections, dividend stocks that offer consistent payouts and potential for capital appreciation can be an attractive option for investors seeking reliable income streams.

With the business potentially at an important milestone, we thought we'd take a closer look at Iterum Therapeutics...

MSCI (NYSE:MSCI) plans to reclassify Greece from Emerging Market to Developed Market status in its equity indexes. The company is also partnering with Syntax Data to expand its ADR index offerings for financial advisers in the US. These changes affect how global capital is allocated to Greek equities and how advisers access international exposure through US listed securities. MSCI is best known for its global equity indexes that many asset managers and ETFs use as benchmarks, so its country...

We can readily understand why investors are attracted to unprofitable companies. For example, Annexon ( NASDAQ:ANNX...

Creative Medical Technology Holdings, Inc. ( NASDAQ:CELZ ) is possibly approaching a major achievement in its business...

Potential LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) shareholders may wish to note that the President, Evert...

The market seemed underwhelmed by the solid earnings posted by Adobe Inc. ( NASDAQ:ADBE ) recently. Along with the...

Market forces rained on the parade of MeiraGTx Holdings plc ( NASDAQ:MGTX ) shareholders today, when the analysts...

Volvo Cars has converted its outstanding shareholder loans to Polestar Automotive Holding UK (NasdaqGM:PSNY) into equity, changing the mix of Polestar’s capital structure. The two companies also agreed to concentrate future manufacturing of the Polestar 3 in the U.S., expanding their existing production collaboration. For investors watching NasdaqGM:PSNY, these moves come against a backdrop of a share price at $18.42 and a long term track record that includes a 41.5% decline over the past...

Capital raise potential and what it could mean for XPLR Infrastructure (XIFR) XPLR Infrastructure (XIFR) has filed a US$300 million shelf registration for its common units, giving the partnership flexibility to issue equity as funding needs or investment plans emerge. See our latest analysis for XPLR Infrastructure. The shelf filing comes as XIFR’s share price sits at US$10.62, with a 1 day share price return of 4.94% and a 1 year total shareholder return of 13.83%. The 3 year total...

Alnylam Pharmaceuticals has reported new clinical and real world data on its RNAi therapy vutrisiran in ATTR-CM, highlighting durable benefits in quality of life and reductions in advanced disease progression and mortality. The company has also shared pooled Phase 2 safety data for zilebesiran that supports its move into a global Phase 3 trial in hypertension and cardiovascular risk reduction. For investors tracking NasdaqGS:ALNY, this update centers on the company’s core RNAi franchise and...

UP Fintech Holding Limited recently reported its fourth-quarter and full-year 2025 results, with Q4 revenue of US$175.57 million and net income of US$45.23 million, and full-year revenue of US$612.06 million and net income of US$170.9 million, all higher than the prior year. The sharp rise in basic earnings per share from continuing operations to US$0.96 for 2025, up from US$0.375 a year earlier, highlights a significant improvement in profitability. We will now examine how this strong...

Wondering if National Health Investors is priced fairly today or if the current share price leaves some room on the table? This overview walks through what the recent numbers may be saying about value. The stock closed at US$80.86, with returns of 5.2% year to date and 14.2% over the last year, while the past 7 and 30 days have seen declines of 2.1% and 3.8% respectively. Recent coverage has focused on how real estate investment trusts are responding to changing conditions in healthcare...

Wondering whether GEO Group at around US$16.81 is starting to look like value or a value trap? This breakdown will help you frame the stock in numbers, not noise. The share price has moved around recently, with a 0.8% decline over the past week, an 11.8% gain over 30 days, a 5.5% return year to date and a 43.8% decline over the last year, set against a 113.9% return over 3 years and 115.5% over 5 years. Recent attention on GEO Group has focused on its role in private corrections and...